Description: Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.
Home Page: www.nicox.com
2405 Route Des Dolines Drakkar D
Valbonne,
06560
France
Phone:
33 4 97 24 53 00
Officers
| Name | Title |
|---|---|
| Dr. Michele Garufi Ph.D. | Co-Founder & Director |
| Mr. Andreas Rutger Segerros M.B.A., M.Sc. | Chief Exec. Officer |
| Ms. Sandrine Gestin | VP of Fin. |
| Mr. Doug Hubatsch | Exec. VP & Chief Scientific Officer |
| Ms. Emmanuelle Pierry | Gen. Counsel & Head of Legal Affairs |
| Dr. Gavin M. Spencer | Exec. VP, Chief Bus. Officer & Head of Corp. Devel. |
| Dr. Ramesh Krishnamoorthy | Sr. Director and Head of Late Stage CMC & Quality Control |
| Dr. Jose Boyer | Consultant |
| Dr. Ennio Ongini Ph.D. | Consultant |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0234 |
| Price-to-Sales TTM: | 8.2923 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 32 |